Pulmonary Hypertension in End-stage Pulmonary Sarcoidosis: Therapeutic Effect of Sildenafil?

Journal of Heart and Lung Transplantation

Volumn 27, Issue 3, 2008, Pages 329-334

  Milman, Nils ^a   Burton, Christopher M ^a   Iversen, Martin ^a   Videbæk, Regitze ^a   Jensen, Claus V ^a   Carlsen, Jørn ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART CATHETERIZATION; HEART INDEX; HEART OUTPUT; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG TRANSPLANTATION; MALE; MORBIDITY; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SARCOIDOSIS;

ADULT; BLOOD PRESSURE; CARDIAC OUTPUT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PIPERAZINES; PREVALENCE; PURINES; RETROSPECTIVE STUDIES; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 40649090145     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.11.576     Document Type: Article

References (25)

1. Sulica R., Teirstein A.S., Kakarla S., et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 128 (2005) 1483-1489
2. Shorr A.F., Helman D.L., Davies D.B., and Nathan S.D. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 25 (2005) 783-788
3. Galie N., Torbicki A., Barst R., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25 (2004) 2243-2278
4. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New Eng J Med 353 (2005) 2148-2157
5. Chua R., Keogh A., and Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant 24 (2005) 498-500
6. Kulkarni A., Singh T.P., Sarnaik A., Walters H.L., and Delius R. Sildenafil for pulmonary hypertension after heart transplantation. J Heart Lung Transplant 23 (2004) 1441-1444
7. Milman N., Burton C., Andersen C.B., Carlsen J., and Iversen M. Lung transplantation for end-stage pulmonary sarcoidosis: outcome in a series of seven consecutive patients. Sarcoid Vasc Diffuse Lung Dis 22 (2005) 222-228
8. Shorr A.F., Davies D.B., and Nathan S.D. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 124 (2003) 922-928
9. Moller D.R. Treatment of sarcoidosis-from a basic science point of view. J Intern Med 253 (2003) 31-40
10. Barst R.J., and Ratner S.J. Sarcoidosis and reactive pulmonary hypertension. Arch Intern Med 145 (1985) 2112-2114
11. Damuth T.E., Bower J.S., Cho K., and Dantzker D.R. Major pulmonary artery stenosis causing pulmonary hypertension in sarcoidosis. Chest 78 (1980) 888-891
12. Portier F., Lerebours-Pigeonniere G., Thiberville L., et al. Sarcoidosis simulating a pulmonary veno-occlusive disease. Rev Mal Respir 8 (1991) 101-102 [in French]
13. Smith L.J., Lawrence J.B., and Katzenstein A.A. Vascular sarcoidosis: a rare cause of pulmonary hypertension. Am J Med Sci 285 (1983) 38-44
14. Gluskowski J., Hawrylkiewicz I., Zych D., and Zielinski J. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J 3 (1990) 403-407
15. Nunes H., Humbert M., Capron F., et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 61 (2006) 68-74
16. Rodman D.M., and Lindenfeld J. Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids. Chest 97 (1990) 500-502
17. Preston I.R., Klinger J.R., Landzberg M.J., et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 120 (2001) 866-872
18. Fisher K.A., Serlin D.M., Wilson K.C., et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 130 (2006) 1481-1488
19. Foley R.J., and Metersky M.L. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan. Respiration 75 (2008) 211-214
20. Sharma S., Kashour T., and Philipp R. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Tex Heart Inst J 32 (2005) 405-410
21. Corbin J.D., and Francis S.H. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 274 (1999) 13729-13732
22. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360 (2002) 895-900
23. Lederer D.J., Arcasoy S.M., Wilt J.S., et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174 (2006) 659-664
24. Flaherty K.R., Andrei A.C., Murray S., et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 174 (2006) 803-809
25. Eaton T., Young P., Milne D., and Wells A.U. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 171 (2005) 1150-1157